California Public Employees Retirement System Has $1.47 Billion Stock Position in Johnson & Johnson $JNJ

Key Points

• California Public Employees Retirement System cut its Johnson & Johnson stake by 19.4% in Q1, selling 1,444,253 shares, but still held nearly 6.0 million shares worth about $1.47 billion.
• Johnson & Johnson reported a strong quarter, with EPS of $2.90 and revenue of $25.31 billion, both ahead of analyst expectations, and it raised its FY 2026 guidance to $11.60-$11.75 per share.
• The company also announced a quarterly dividend of $1.34 per share, while analysts remain broadly positive with a consensus rating of Moderate Buy and an average price target of $265.30.

California Public Employees Retirement System lowered its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 19.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,994,988 shares of the company's stock after selling 1,444,253 shares during the period. Johnson & Johnson makes up 0.9% of California Public Employees Retirement System's portfolio, making the stock its 15th biggest position. California Public Employees Retirement System owned approximately 0.25% of Johnson & Johnson worth $1,465,415,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Quadrant Private Wealth Management LLC boosted its position in shares of Johnson & Johnson by 0.5% during the first quarter. Quadrant Private Wealth Management LLC now owns 22,377 shares of the company's stock worth $5,470,000 after buying an additional 109 shares during the period. Ranch Capital Advisors Inc. grew its position in shares of Johnson & Johnson by 3.7% in the 1st quarter. Ranch Capital Advisors Inc. now owns 15,940 shares of the company's stock valued at $3,896,000 after acquiring an additional 570 shares during the period. Heartland Bank & Trust Co raised its stake in Johnson & Johnson by 70.9% in the first quarter. Heartland Bank & Trust Co now owns 15,382 shares of the company's stock valued at $3,760,000 after buying an additional 6,381 shares during the period. Zhang Financial LLC lifted its stake in shares of Johnson & Johnson by 35.3% during the 1st quarter. Zhang Financial LLC now owns 18,324 shares of the company's stock worth $4,479,000 after buying an additional 4,783 shares during the last quarter. Finally, Simon Quick Advisors LLC grew its position in shares of Johnson & Johnson by 1.6% in the first quarter. Simon Quick Advisors LLC now owns 14,067 shares of the company's stock valued at $3,439,000 after purchasing an additional 219 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company's stock, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $252.93 on Monday. The firm's fifty day moving average price is $239.82 and its two-hundred day moving average price is $234.82. The stock has a market cap of $608.86 billion, a PE ratio of 29.31, a PEG ratio of 2.39 and a beta of 0.24. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a fifty-two week low of $162.78 and a fifty-two week high of $269.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The company had revenue of $25.31 billion during the quarter, compared to analysts' expectations of $25.06 billion. During the same period in the prior year, the company earned $2.77 EPS. Johnson & Johnson's revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.68 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson's payout ratio is 62.11%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Daiwa Securities Group lifted their target price on Johnson & Johnson from $237.00 to $246.00 and gave the stock an "outperform" rating in a report on Thursday, April 16th. JPMorgan Chase & Co. boosted their price objective on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a "neutral" rating in a report on Wednesday, April 15th. Scotiabank reaffirmed an "outperform" rating and set a $305.00 target price on shares of Johnson & Johnson in a report on Thursday. Citigroup increased their price target on Johnson & Johnson from $285.00 to $298.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. Finally, Freedom Capital upgraded Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $265.30.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson beat Q2 earnings and revenue estimates, showing solid demand and execution in its core business. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why
• Positive Sentiment: The company raised its 2026 guidance after the report, reinforcing confidence in its growth outlook and pipeline momentum. Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat
• Positive Sentiment: Guggenheim reaffirmed its Buy rating and set a $270 price target, signaling continued analyst confidence. Benzinga article on Guggenheim rating reaffirmation
• Positive Sentiment: Some market commentary suggests the post-earnings pullback could be an opportunity to buy JNJ on strength after a run to 52-week highs. Why Johnson and Johnson's Earnings Dip Looks Like a Buying Opportunity
• Neutral Sentiment: Investors are also digesting the full Q2 earnings call transcript and several commentary pieces framing the company’s growth beyond legacy drugs and its collaboration announcements. Full Transcript: Johnson & Johnson Q2 2026 Earnings Call
• Negative Sentiment: Despite the earnings beat, the stock fell because MedTech results missed expectations, creating concern that one important division is lagging behind the company’s otherwise solid performance. J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.